Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T | ISIN: JP3475350009 | Ticker-Symbol: D4S
Tradegate
03.07.25 | 08:35
19,005 Euro
-3,09 % -0,605
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
18,98519,13010:19
19,01519,16510:14

Aktuelle News zur DAIICHI SANKYO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.06.AstraZeneca, Daiichi's Datroway scores its 2nd FDA approval-this time in lung cancer subset21
24.06.Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway3
24.06.AZ, Daiichi get Datroway nod in lung cancer on second try1
24.06.FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer4
24.06.AstraZeneca/Daiichi Sankyo's Datroway granted FDA accelerated approval for lung cancer2
24.06.FDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC3
DAIICHI SANKYO Aktie jetzt für 0€ handeln
24.06.AstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M2
24.06.AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer469LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed...
► Artikel lesen
24.06.US approves AstraZeneca, Daiichi's treatment for lung cancer5
07.06.Daiichi, Shell partner for RE push25
04.06.Daiichi Sankyo struck gold with 'ADC' cancer drugs. Its new CEO has to figure out what's next.13
02.06.Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC9
31.05.AstraZeneca And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial1.346LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated...
► Artikel lesen
31.05.AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial4
30.05.Daiichi Sankyo and MSD withdraw US application for lung cancer BLA3
29.05.Merck, Daiichi pull approval application for ADC in lung cancer20
29.05.Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint5
29.05.MSD and Daiichi Sankyo pull HER3-DXd's FDA filing3
29.05.Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan632KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited...
► Artikel lesen
29.05.Merck, Daiichi Sankyo pull marketing application for lung cancer therapy5
Weiter >>
115 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1